Healthcare Industry News: Bard
News Release - January 4, 2011
BSD Medical Appoints Sunita Pargass as MicroThermX Director of MarketingSALT LAKE CITY--(Healthcare Sales & Marketing Network)-- BSD Medical Corporation (NASDAQ:BSDM ) (Company or BSD) announced today the addition of Sunita Pargass as the Director of Marketing for the MicroThermX Microwave Ablation product line. Ms. Pargass has 20 years of experience in the medical industry, including marketing, sales, market analysis, product positioning, new product launches and promotional activities. She has extensive experience in marketing medical products to the field of interventional radiology, which is the target market for the Company’s ablation product line. She most recently served as Senior Product Manager for Bard Access Systems, Inc., a division of C.R. Bard.
Ms. Pargass has been instrumental in successfully launching a number of new medical product lines throughout the world. Her responsibilities at BSD will include a focus on the product launch of the new MicroThermX Microwave Ablation System. Ms. Pargass will provide marketing management and support for the extensive worldwide distribution network that the Company is bringing on line to capitalize on the large opportunity in the ablation market.
“To ensure our success, we must understand how we should be positioned in the marketplace and provide our customers with a world-class experience with respect to service, quality, and total customer satisfaction,” said Harold Wolcott, BSD’s President. “The Company is establishing an extensive network of top-notch distributors and marketing and sales personnel to ensure we meet our sales goals. Sunita will be a significant contributor to our business success.”
Ms. Pargass has an MBA from Emory University and an MS in chemical engineering and a BS in bioengineering from Columbia University.
About the MicroThermX Microwave Ablation System
The MTX-180 is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MTX-180 is the first of its kind that allows delivery of higher power levels using a single generator. The MTX-180 utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MTX-180 introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MTX-180 for ablation of soft tissue. BSD has also received CE Marking for the MTX-180 System. CE marking approval allows BSD to market the MTX system in the 30 countries that comprise the European Union (EU) and the European Free Trade Association (EFTA). CE marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MTX to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.